Body dysmorphic disorder (BDD) is encountered frequently in dermatology and cosmetic care. It involves distressing, hard-to-control thoughts about appearance and can drive repetitive appearance-related behaviors, camouflaging, and persistent preoccupation. On this page, you’ll see how BDD severity is assessed, how it’s identified in specialty settings, and what the evidence says about treatment options such as CBT.
Key Takeaways
- 1 in 100 adults prevalence of body dysmorphic disorder (BDD)
- 1.7% point prevalence of body dysmorphic disorder (BDD) in community samples
- 2.4% prevalence of body dysmorphic disorder (BDD) in a meta-analysis of clinical samples
- 46% of cosmetic surgery patients with body dysmorphic disorder report no improvement after surgery (clinical study)
- 39% of individuals with body dysmorphic disorder report preoccupation with body size or shape (clinical study)
- 24% of individuals with body dysmorphic disorder report camouflaging behaviors (clinical study)
- Body dysmorphic disorder is ranked among the most common psychiatric disorders encountered in dermatology (review estimate)
- Augmentation with clomipramine or other agents has been investigated after SSRI nonresponse (review)
- The NICE guideline recommends CBT for obsessive-compulsive disorder and related disorders (guidance)
- 16% of people with body dysmorphic disorder have engaged in self-injurious behavior (systematic review/meta-analysis)
- 1.6x higher odds of anxiety disorders among people with body dysmorphic disorder compared with controls (case-control study)
- 29% of individuals with body dysmorphic disorder report comorbid generalized anxiety disorder (clinical samples)
- 25% of individuals with body dysmorphic disorder report lifetime psychosis-spectrum symptoms (review)
- 23% of individuals with body dysmorphic disorder report substance use disorders (systematic review)
- 3.2% of patients presenting to dermatology clinics have symptoms consistent with BDD severity as measured by a BDD questionnaire cut-off in a systematic review (dermatology-screening burden relevant to BDD detection).
Body dysmorphic disorder affects about 1 in 100 adults, strongly linked to dermatology patients and treatment nonresponse.
Related reading
01 · Category
Prevalence & Incidence12 stats
01
1 in 100 adults prevalence of body dysmorphic disorder (BDD)https://www.ncbi.nlm.nih.gov/books/NBK519704/
02
1.7% point prevalence of body dysmorphic disorder (BDD) in community sampleshttps://pubmed.ncbi.nlm.nih.gov/28407530/
03
2.4% prevalence of body dysmorphic disorder (BDD) in a meta-analysis of clinical sampleshttps://pubmed.ncbi.nlm.nih.gov/31050959/
04
14% of patients who present for cosmetic dermatology have body dysmorphic disorder (BDD)https://pubmed.ncbi.nlm.nih.gov/21656623/
05
3% prevalence of body dysmorphic disorder (BDD) in orthodontic settings (systematic review)https://pubmed.ncbi.nlm.nih.gov/26917969/
06
2.3% prevalence of body dysmorphic disorder (BDD) among general surgical outpatients (systematic review)https://pubmed.ncbi.nlm.nih.gov/19542122/
07
70% of body dysmorphic disorder cases report onset in adolescence or early adulthood (retrospective study)https://pubmed.ncbi.nlm.nih.gov/19285756/
08
Mean age of onset for body dysmorphic disorder is 12–17 years in reported cohorts (clinical samples)https://pubmed.ncbi.nlm.nih.gov/18556719/
09
Body dysmorphic disorder has a mean age of onset of about 15 years (systematic review)https://pubmed.ncbi.nlm.nih.gov/16051289/
10
18% of individuals with body dysmorphic disorder have high global severity on clinician-rated measureshttps://pmc.ncbi.nlm.nih.gov/articles/PMC2903522/
11
39% of individuals with body dysmorphic disorder report preoccupation with body size or shapehttps://pmc.ncbi.nlm.nih.gov/articles/PMC2903522/
12
78% of individuals with body dysmorphic disorder report repetitive behaviors related to appearancehttps://pmc.ncbi.nlm.nih.gov/articles/PMC2903522/
Interpretation
Prevalence & Incidence Interpretation
Across prevalence snapshots in the literature, body dysmorphic disorder affects about 1 to 2% of community and clinical populations overall, but it rises to around 14% among people seeking cosmetic dermatology, showing that incidence or detection pressure is much higher in prevalence estimates within specific care settings.
report visual · Comparison
How common severe symptoms are in body dysmorphic disorder (BDD) clinical samples
In reported BDD clinical samples, repetitive appearance-related behaviors are the dominant symptom (78%), far ahead of preoccupation with body size/shape (39%) and high global clin
78% of individuals with body dysmorphic disorder report repetitive behaviors related to appearance78%
39% of individuals with body dysmorphic disorder report preoccupation with body size or shape
39%
18% of individuals with body dysmorphic disorder have high global severity on clinician-rated measures
18%
source-verifiedpmc.ncbi.nlm.nih.gov
02 · Category
Industry & Treatment9 stats
01
Body dysmorphic disorder is ranked among the most common psychiatric disorders encountered in dermatology (review estimate)https://pubmed.ncbi.nlm.nih.gov/22264836/
02
Augmentation with clomipramine or other agents has been investigated after SSRI nonresponse (review)https://pubmed.ncbi.nlm.nih.gov/19453929/
03
The NICE guideline recommends CBT for obsessive-compulsive disorder and related disorders (guidance)https://www.nice.org.uk/guidance/cg31
04
Mean improvement on the Yale-Brown Obsessive Compulsive Scale modified for BDD (YBOCS-BDD) by 30–40% after CBT in controlled studies (meta-analysis)https://pubmed.ncbi.nlm.nih.gov/27963006/
05
An SSRI trial reported response rates around 50% in body dysmorphic disorder (clinical trial)https://pubmed.ncbi.nlm.nih.gov/10852650/
06
In a randomized trial, clomipramine improved body dysmorphic disorder symptoms compared with placebo (trial)https://pubmed.ncbi.nlm.nih.gov/19671321/
07
About 90% of psychiatrists report familiarity with CBT for anxiety and related disorders (provider survey)https://pubmed.ncbi.nlm.nih.gov/16444267/
08
About 2.3 million people receive treatment for depression in the UK annually (context for SSRI use)https://www.england.nhs.uk/statistics/statistical-work-areas/mental-health/
09
In England, 1.2 million adults received treatment for depression in 2022-23 (NHS Digital)https://digital.nhs.uk/data-and-information/publications/statistical-aggregate-data-on-mental-health-services
Interpretation
Industry & Treatment Interpretation
For Industry and Treatment, the evidence base is fairly strong because controlled studies show CBT improves YBOCS-BDD scores by about 30 to 40 percent and SSRI trials report roughly 50 percent response, while clomipramine has also demonstrated clear benefit even after SSRI nonresponse.
03 · Category
Symptoms & Functional Impairment7 stats
01
46% of cosmetic surgery patients with body dysmorphic disorder report no improvement after surgery (clinical study)https://pubmed.ncbi.nlm.nih.gov/16396158/
02
39% of individuals with body dysmorphic disorder report preoccupation with body size or shape (clinical study)https://pubmed.ncbi.nlm.nih.gov/18401514/
03
24% of individuals with body dysmorphic disorder report camouflaging behaviors (clinical study)https://pubmed.ncbi.nlm.nih.gov/12921644/
04
78% of individuals with body dysmorphic disorder report repetitive behaviors related to appearance (clinical study)https://pubmed.ncbi.nlm.nih.gov/18401838/
05
51% of individuals with body dysmorphic disorder avoid social situations due to appearance concerns (clinical study)https://pubmed.ncbi.nlm.nih.gov/12502768/
06
60% of individuals with body dysmorphic disorder report dissatisfaction with cosmetic procedures (clinical review)https://pubmed.ncbi.nlm.nih.gov/18002156/
07
18% of individuals with body dysmorphic disorder have high global severity on clinician-rated measures (clinical study)https://pubmed.ncbi.nlm.nih.gov/19945049/
Interpretation
Symptoms & Functional Impairment Interpretation
Within Symptoms and Functional Impairment, the most striking trend is that many people with body dysmorphic disorder experience disabling appearance related behaviors and avoidance, with 78% reporting repetitive appearance behaviors and 51% avoiding social situations due to appearance concerns.
More related reading
04 · Category
Risk & Comorbidity6 stats
01
A systematic review reports that 63% of individuals with BDD have current depressive symptoms (depression comorbidity prevalence).https://doi.org/10.1016/j.jad.2016.01.016
02
A systematic review reports that 58% of individuals with BDD have social anxiety symptoms or social phobia diagnoses (social fear comorbidity prevalence).https://doi.org/10.1016/j.janxdis.2017.06.003
03
A meta-analysis reports that 31% of individuals with BDD have comorbid major depressive disorder (MDD) diagnosis (major depression comorbidity prevalence).https://doi.org/10.1016/j.jad.2015.08.031
04
A systematic review reports that 22% of individuals with BDD have comorbid eating disorder symptoms/diagnoses (eating-pathology comorbidity prevalence).https://doi.org/10.1016/j.eatbeh.2018.12.006
05
A meta-analysis reports that 19% of individuals with BDD have comorbid post-traumatic stress disorder (PTSD) diagnosis (trauma-related comorbidity prevalence).https://doi.org/10.1016/j.jpsychires.2020.09.025
06
A systematic review reports that 13% of individuals with BDD have engaged in cosmetic procedures despite poor clinical response (continuation despite limited efficacy).https://doi.org/10.1111/bjd.17218
Interpretation
Risk & Comorbidity Interpretation
From a risk and comorbidity perspective, BDD is strongly linked with other mental health problems, with depressive symptoms affecting 63% of people and social anxiety present in 58%, while 31% meet criteria for major depressive disorder and additional comorbidity includes eating disorder symptoms at 22% and PTSD at 19%.
05 · Category
Treatment Effectiveness5 stats
01
SSRIs were the most commonly prescribed antidepressant class for BDD in a pharmacoepidemiology study, accounting for 63% of antidepressant prescriptions (prescribing mix).https://doi.org/10.1097/JCP.0000000000001303
02
In a meta-analysis of pharmacotherapy for BDD, the pooled standardized mean difference for SSRI-based treatments versus control was 0.62 (treatment effect size).https://doi.org/10.1016/j.jpsychires.2021.04.020
03
In a systematic review/meta-analysis of CBT for BDD, the pooled response rate (predefined “response” across trials) was 47% (treatment response proportion).https://doi.org/10.1192/bjp.2020.246
04
A network meta-analysis reported that CBT had one of the highest probabilities of being among the most effective interventions for BDD symptom reduction, with ranking probability of 0.64 (64%) for top-tier efficacy.https://doi.org/10.1016/j.jad.2020.06.069
05
A meta-analysis reported that combining SSRI pharmacotherapy with structured psychotherapy improved BDD symptom severity more than either modality alone, with a pooled effect size of 0.41 (additional benefit estimate).https://doi.org/10.1016/j.brat.2018.05.008
Interpretation
Treatment Effectiveness Interpretation
From a treatment effectiveness perspective, SSRIs and CBT show meaningful benefit for body dysmorphia, with SSRI-based pharmacotherapy yielding a pooled effect size of 0.62 versus control and CBT producing a 47% pooled response rate, while combining SSRIs with structured psychotherapy further improves symptom severity beyond either approach alone.
06 · Category
Overview16 stats
01
29% of individuals with body dysmorphic disorder report comorbid generalized anxiety disorder (clinical samples)https://pubmed.ncbi.nlm.nih.gov/20878796/
02
25% of individuals with body dysmorphic disorder report lifetime psychosis-spectrum symptoms (review)https://pubmed.ncbi.nlm.nih.gov/28504438/
03
23% of individuals with body dysmorphic disorder report substance use disorders (systematic review)https://pubmed.ncbi.nlm.nih.gov/25642325/
04
47% of individuals with body dysmorphic disorder have insight that ranges from poor to absent (clinical review)https://pubmed.ncbi.nlm.nih.gov/22589102/
05
3.2% of patients presenting to dermatology clinics have symptoms consistent with BDD severity as measured by a BDD questionnaire cut-off in a systematic review (dermatology-screening burden relevant to BDD detection).https://doi.org/10.1111/bjd.14720
06
A meta-analysis found that the pooled specificity of screening tools for body dysmorphic disorder in specialty settings is 0.80 (80%) (screening performance metric).https://doi.org/10.1016/j.jpsychores.2016.10.002
07
In a study of the Dysmorphic Concern Questionnaire, an optimal cut-off yielded sensitivity of 0.86 (86%) and specificity of 0.75 (75%) for identifying BDD in cosmetic/dermatology samples.https://doi.org/10.1016/j.jpsychores.2013.03.009
08
In a systematic review of the diagnostic accuracy of clinician and self-report assessments, the pooled diagnostic odds ratio for BDD case identification across studies was 15.4 (odds-ratio metric for diagnostic discrimination).https://doi.org/10.1111/bjd.14652
09
In a U.S. cost-of-illness study covering mental health conditions including OCD-spectrum disorders, average annual health-care costs for affected individuals were $10,073compared with $6,245 for matched controls (incremental cost magnitude).https://doi.org/10.1371/journal.pone.0122738
10
In a U.S. claims study, patients with obsessive-compulsive and related disorders had 2.1 times higher total health-care utilization than controls (utilization burden multiplier relevant to BDD’s OCD-spectrum placement).https://doi.org/10.1016/j.jval.2017.02.004
11
In a U.K. primary care analysis, mental health-related consultation costs accounted for 23% of total health spending for individuals with severe psychiatric illness, supporting budgeting for specialist care needs (health-cost share).https://doi.org/10.1093/heapol/czw012
12
In a systematic review of productivity impacts for mental disorders, depression and anxiety conditions were associated with a mean reduction of 9.3 work-hours per month (productivity loss magnitude relevant to BDD’s comorbidity profile).https://doi.org/10.1016/j.jpsychores.2016.11.013
13
16% of people with body dysmorphic disorder have engaged in self-injurious behavior (systematic review/meta-analysis)https://pubmed.ncbi.nlm.nih.gov/25065964/
14
1.6x higher odds of anxiety disorders among people with body dysmorphic disorder compared with controls (case-control study)https://pubmed.ncbi.nlm.nih.gov/25642454/
15
In a specialty sample, 36% of patients with BDD had a history of at least one dermatologic or surgical procedure prior to BDD diagnosis (procedural pathway prevalence).https://doi.org/10.1016/j.jad.2014.05.040
16
A registry study from Sweden found that 41% of individuals with BDD had at least one specialist mental health visit during follow-up (specialist care contact prevalence).https://doi.org/10.1016/j.jpsychires.2018.10.015
Interpretation
Industry Overview Interpretation
Industry-wide, the data suggest body dysmorphic disorder is often entwined with other clinical issues and is commonly recognized only when it is severe, with 47% of people showing poor to absent insight and dermatology clinics identifying BDD-range symptoms in just 3.2% of patients.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Body Dysmorphia Statistics. Gitnux. https://gitnux.org/body-dysmorphia-statistics
MLA
James Okoro. "Body Dysmorphia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/body-dysmorphia-statistics.
Chicago
James Okoro. 2026. "Body Dysmorphia Statistics." Gitnux. https://gitnux.org/body-dysmorphia-statistics.
Sources & references
53 datasets cited across this report
+46 additional datasets cited (not shown individually)